Filing Flows › Comparisons › SBFM vs GOSS
Sunshine Biopharma vs Gossamer Bio: SBFM and GOSS compared
Sunshine Biopharma is the larger company: $9.3M of revenue in its latest quarter (Q2 2026) against $9.2M for Gossamer Bio (Q2 2026). Sunshine Biopharma is growing faster (-2% against -20% a year earlier). Sunshine Biopharma is more profitable, with an operating margin of -17.4% against -282.2%.
Where the money goes: SBFM and GOSS
Sunshine Biopharma (SBFM) · Q2 2026
Sunshine Biopharma, Q2 2026: revenue $9.3M (-2% year over year), operating margin -17.4%, net loss $1.6M, operating cash flow −$918K. The chart follows the revenue to costs, profit and cash.
Gossamer Bio (GOSS) · Q2 2026
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart follows the revenue to costs, profit and cash.
| Sunshine Biopharma (SBFM) | Gossamer Bio (GOSS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $9.3M | $9.2M |
| Revenue growth, Y/Y | -2% | -20% |
| Operating margin | -17.4% | -282.2% |
| Net earnings | −$1.6M | $16.9M |
| Net margin | -16.9% | 182.9% |
| Operating cash flow | −$918K | −$39.4M |
Questions
Which is bigger, Sunshine Biopharma or Gossamer Bio?
Sunshine Biopharma is the larger company: $9.3M of revenue in its latest quarter (Q2 2026) against $9.2M for Gossamer Bio (Q2 2026).
Is Sunshine Biopharma or Gossamer Bio growing faster?
Sunshine Biopharma is growing faster (-2% against -20% a year earlier).
Which is more profitable, Sunshine Biopharma or Gossamer Bio?
Sunshine Biopharma is more profitable, with an operating margin of -17.4% against -282.2%.
More: Sunshine Biopharma earnings · how Sunshine Biopharma makes money · Gossamer Bio earnings · how Gossamer Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.